Adicet Bio, Inc.
ACET · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.01 | 0.35 | 0.15 |
| FCF Yield | -110.62% | -120.69% | -16.76% | -11.84% |
| EV / EBITDA | -0.41 | 0.42 | -2.02 | -4.71 |
| Quality | ||||
| ROIC | -62.57% | -79.51% | -23.14% | -18.91% |
| Gross Margin | 0.00% | 0.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.79 | 0.66 | 0.64 | 0.82 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | 11.76% | 2,134,767.60% |
| Free Cash Flow Growth | 4.77% | -59.52% | 3.98% | -50.67% |
| Safety | ||||
| Net Debt / EBITDA | 0.35 | 1.02 | 3.66 | 4.25 |
| Interest Coverage | -31,903.75 | 0.00 | -906.89 | -349.05 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 6.35 | 8.03 |